In the absence of ALK mutations, overexpression of ALKL2 potentiates MYCN-driven neuroblastoma in mice, emphasizing the importance of ALK as a therapeutic neuroblastoma target (Borenäs et al., 2021). This evidence concerns the gene MYCN and neuroblastoma.